Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Lunit, a leading AI startup in cancer solutions, secured a strategic investment of $26 million from Guardant Health (Nasdaq: GH). This collaboration aims to innovate the precision oncology landscape and enhance cancer diagnostics. Following this investment, Lunit is set to file for an initial public offering on the Korean Stock Exchange. Notably, Lunit's SCOPE platform demonstrated a 50% improvement in identifying patients suitable for immunotherapy at the ASCO 2021 meeting. Leaders from both companies expressed optimism about advancing cancer care through this partnership.
Guardant Health, Inc. (Nasdaq: GH) will report its financial results for Q2 2021 on August 5, 2021, after the market closes. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET, which will be available for live listening on the company’s website. Guardant Health focuses on precision oncology with proprietary tests like Guardant360® and Guardant Reveal™, aiming to improve patient outcomes and reduce healthcare costs across cancer care stages.
Guardant Health (Nasdaq: GH) has launched two innovative tests for late-stage cancer management: the Guardant360 Response and Guardant360 TissueNext. The Guardant360 Response is a blood-only test that detects changes in circulating tumor DNA (ctDNA), providing early treatment response indicators up to eight weeks prior to traditional methods. The Guardant360 TissueNext offers tissue testing to complement the blood test, ensuring comprehensive patient evaluation. These additions enhance the Guardant360 portfolio, aiming to optimize treatment selection and improve clinical outcomes.
Guardant Health, Inc. (Nasdaq: GH) has appointed Chris Freeman as the Chief Commercial Officer for its oncology business, effective June 8, 2021. Freeman brings extensive experience in managing pharmaceutical brands, which will aid in the company's efforts to expand its oncology portfolio for advanced and early-stage cancers. CEO Helmy Eltoukhy emphasized Freeman's role in developing commercial strategies to enhance growth across various market segments.
Guardant Health reveals promising early results from the LUNAR-2 blood test at the 2021 ASCO Annual Meeting, demonstrating a 91% sensitivity for detecting early-stage colorectal cancer (CRC) with a specificity of 94%. With only 68% of adults over 50 screened for CRC, this test may improve compliance with CDC goals. The ECLIPSE trial, a 10,000-patient study, is underway to validate these findings and support FDA approval. Guardant's CEO emphasizes the test's effectiveness in both asymptomatic and symptomatic patients, showcasing its potential for clinical adoption in average-risk populations.
Guardant Health announces FDA approval for its Guardant360 CDx test, the first liquid biopsy companion diagnostic for KRAS G12C mutation profiling in patients with non-small cell lung cancer (NSCLC). This approval, based on CodeBreaK 100 trial data, identifies patients eligible for LUMAKRAS™ (sotorasib), a targeted therapy for KRAS G12C mutation. Lung cancer is the leading cancer death cause in the U.S., and this development enhances personalized treatment options significantly.
Guardant Health, Inc. (Nasdaq: GH) has filed a lawsuit against Natera, Inc. for false advertising and unfair competition related to misleading claims about Guardant's new oncology test, Guardant Reveal™. The lawsuit seeks to prevent Natera from disseminating false information and demands corrective actions. Guardant Reveal™ is a groundbreaking blood-only liquid biopsy test designed to help early-stage colorectal cancer survivors detect residual disease and recurrences. This legal action arises from allegations that Natera misrepresents the test's efficacy, impacting patient treatment opportunities.
Guardant Health announces FDA approval for the Guardant360®CDx liquid biopsy test, the first companion diagnostic for Janssen Biotech’s RYBREVANT™. Designed for tumor mutation profiling in non-small cell lung cancer (NSCLC), it identifies patients with EGFR exon 20 insertion mutations who may benefit from targeted therapy after chemotherapy. With lung cancer being the leading cause of cancer death, this approval marks a significant advancement in treatment options. The Guardant360 CDx test offers rapid genomic results from a blood draw, enhancing oncologists' ability to personalize treatment for patients.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
